Literature DB >> 7340879

Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.

A R Boobis, M J Brodie, G C Kahn, E L Toverud, I A Blair, S Murray, D S Davies.   

Abstract

1 The metabolism of antipyrine to its three main oxidative metabolites, 4-hydroxyantipyrine, 3-hydroxymethylantipyrine and norphenazone was investigated in vivo and in vitro in separate groups of subjects with normal hepatic function and in the same group of patients with suspected liver disease. 2 The rank order for the rate of formation of the three metabolites of antipyrine was similar in vivo and in vitro. 3 There was no significant correlation between the rates of formation of any pair of antipyrine metabolites either in vivo or in vitro. 4 Despite this there was a significant correlation between the in vivo and in vitro rates for formation of each of the three metabolites in the same group of patients. 5 It is concluded that determination of rates of formation of antipyrine metabolites from their excretion in urine provides an indication of the activity of the enzymes involved in their formation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7340879      PMCID: PMC1401933          DOI: 10.1111/j.1365-2125.1981.tb01305.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  23 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  The metabolism of (ureyl-14C)tolbutamide in vitro and in vivo in man.

Authors:  F J Darby; R K Grundy
Journal:  Life Sci       Date:  1973-07-16       Impact factor: 5.037

Review 3.  Multiplicity of mammalian microsomal cytochromes P-45.

Authors:  A Y Lu; S B West
Journal:  Pharmacol Rev       Date:  1979-12       Impact factor: 25.468

4.  Correlation of the plasma elimination of antipyrine and the appearance of 4-hydroxy antipyrine in the urine of man.

Authors:  D H Huffman; D W Shoeman; D L Azarnoff
Journal:  Biochem Pharmacol       Date:  1974-01-15       Impact factor: 5.858

5.  Genetic control of drug levels in man: antipyrine.

Authors:  E S Vesell; J G Page
Journal:  Science       Date:  1968-07-05       Impact factor: 47.728

6.  Rapid gas-liquid chromatographic estimation of antipyrine in plasma.

Authors:  L F Prescott; K K Adjepon-Yamoah; E Roberts
Journal:  J Pharm Pharmacol       Date:  1973-03       Impact factor: 3.765

7.  Antipyrine as an in vitro probe of mixed function oxidase activity [proceeding].

Authors:  G C Kahn; A R Boobis; I Blair; M J Brodie; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1980-03       Impact factor: 4.335

8.  An improved combined gas chromatographic mass spectrometric assay for the estimation of norphenazone in urine.

Authors:  S Murray
Journal:  Biomed Mass Spectrom       Date:  1980-04

9.  Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens.

Authors:  A R Boobis; M J Brodie; G C Kahn; D R Fletcher; J H Saunders; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1980-01       Impact factor: 4.335

10.  Correlations between cytochrome P-450 and oxidative metabolism of benzo[a]pyrene and 7-ethoxycoumarin in human liver in vitro and antipyrine elimination in vivo.

Authors:  O Pelkonen; E Sotaniemi; O Tokola; J T Ahokas
Journal:  Drug Metab Dispos       Date:  1980 Jul-Aug       Impact factor: 3.922

View more
  28 in total

1.  An examination of a possible pharmacokinetic interaction between nifedipine and antipyrine.

Authors:  T Edeki; A Johnston; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Disposition of antipyrine in African patients with Hodgkin's lymphoma.

Authors:  F D Juma
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

3.  Antipyrine metabolism in acute hepatic porphyria in relapse and remission.

Authors:  G G Birnie; K E McColl; G G Thompson; M R Moore; A Goldberg; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

Review 4.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

5.  Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine.

Authors:  G T Blyden; D J Greenblatt; B W LeDuc; J M Scavone
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach.

Authors:  J H Schellens; J H van der Wart; M Danhof; E A van der Velde; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

7.  The disposition of antipyrine and its metabolites in young and elderly healthy volunteers.

Authors:  J Posner; M Danhof; M W Teunissen; D D Breimer; P D Whiteman
Journal:  Br J Clin Pharmacol       Date:  1987-07       Impact factor: 4.335

8.  The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women.

Authors:  K Groen; M A Horan; N A Roberts; R S Gulati; B Miljkovic; E J Jansen; V Paramsothy; D D Breimer; C F van Bezooijen
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

9.  Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver.

Authors:  G C Kahn; A R Boobis; S Murray; M J Brodie; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

10.  Effect of the removal of individual antiepileptic drugs on antipyrine kinetics, in patients taking polytherapy.

Authors:  P N Patsalos; J S Duncan; S D Shorvon
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.